indication

Psychotic Disorders

Competitive landscape projected to EPI-CAL data network’s launch window

as of 2026-07-01
Competitive set
27
15 approved · 12 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
127 events
2020
2024
2028
2032
2036
2040
2044
2048
today
EPI-CAL data network launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Risperidone
US-approved 1993 · RISPERDAL
Phase 4110 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugRecruiting
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 463 trials
OwnerEli Lilly and Company
Protection2041
drugRecruiting
Aripiprazole
US-approved 2002 · ABILIFY
Phase 461 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugRecruiting
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 438 trials
OwnerAstraZeneca
Protection—
drugRecruiting
Ziprasidone
US-approved 2001 · Geodon
Phase 430 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 426 trials
OwnerJohnson & Johnson
Protection2041
drugRecruiting
Clozapine
US-approved 1989 · Clozaril
Phase 417 trials
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 414 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugRecruiting
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 48 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 47 trials
OwnerSumitomo Pharmaceuticals America
Protection2031
drugRecruiting
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 46 trials
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 46 trials
OwnerOrganon and Co
Protection2033
drugRecruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 35 trials
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 43 trials
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugCompleted
Iloperidone
US-approved 2009 · FANAPT
Phase 42 trials
OwnerVanda Pharmaceuticals
Protection2031
drugRecruiting
Cannabidiol
Pipeline · Phase 3
Phase 311 trials
OwnerCentral Institute of Mental Health, Mannheim
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 48 trials
OwnerSanofi
Protection2038
drugCompleted
Minocycline
Pipeline · Phase 4
Phase 45 trials
OwnerPakistan Institute of Living and Learning
Protection—
drugCompleted
Perphenazine
Pipeline · Phase 4
Phase 44 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Sarcosine
Pipeline · Phase 2
Phase 23 trials
OwnerChina Medical University Hospital
Protection—
drugCompleted
Flupentixol
Pipeline · Phase 4
Phase 42 trials
OwnerTechnical University of Munich
Protection—
drugCompleted
Chlorpromazine
Pipeline · Phase 4
Phase 41 trial
OwnerMelbourne Health
Protection—
drugCompleted
Ulotaront
Pipeline · Phase 1
Phase 11 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection—
drugCompleted
Brilaroxazine
Pipeline · Phase 2
Phase 21 trial
OwnerReviva Pharmaceuticals
Protection—
drugCompleted
Sulpiride
Pipeline · Phase 4
Phase 41 trial
OwnerTechnical University of Munich
Protection—
drugCompleted
Zuclopenthixol
Pipeline · Phase 4
Phase 41 trial
OwnerBirte Glenthoj
Protection—
drugCompleted
Fluphenazine
Pipeline · Phase 4
Phase 41 trial
OwnerHannover Medical School
Protection—

Market size

prevalence as a range, not a number